Understanding Parkinson’s

1. What is Parkinson’s disease?

Parkinson’s disease (PD) is a chronic and progressive movement disorder that involves the malfunction
and death of vital nerve cells in the brain, called neurons. Some of these dying neurons produce
dopamine, a chemical that sends messages to the part of the brain that controls movement and
coordination. As Parkinson’s progresses, the amount of dopamine produced in the brain decreases,
leaving a person unable to control movement normally.

2. What are the symptoms of Parkinson’s?

The four key motor symptoms of Parkinson’s disease are tremor of the hands, arms, legs or jaw; muscle
rigidity or stiffness of the limbs and trunk; slowness of movement (bradykinesia); and postural instability
(impaired balance and coordination). Other common symptoms may include pain; dementia or
confusion; fatigue; sleep disturbances; depression; constipation; cognitive changes; fear or anxiety; and
urinary problems. All of these symptoms can vary from person to person.

3. How many people have Parkinson’s?

An estimated 10 million people worldwide live with Parkinson’s disease. As many as one million
individuals live with Parkinson’s, which is more than the combined number of people diagnosed with
multiple sclerosis, muscular dystrophy and Lou Gehrig’s disease. Approximately 60,000 are diagnosed
with Parkinson’s disease each year, and this number does not reflect the thousands of cases that go
undetected. Incidence of Parkinson’s increases with age, but an estimated four percent of people with
Parkinson’s are diagnosed before the age of 50. Statistics have shown that men are slightly more likely
to have Parkinson’s disease than women.

4. What causes Parkinson’s?

As is the case with many neurological disorders, the cause of Parkinson’s disease is not known. However,
scientists and researchers are working diligently to uncover the possible cause(s), including genetic and
environmental factors, of Parkinson’s disease.

5. Is Parkinson’s inherited?

Although the vast majority of Parkinson’s cases are not directly inherited, researchers have discovered
several genes that can cause the disease in a small number of families. Research on these rare genetic
forms is contributing greatly to advancing the understanding of all forms of Parkinson’s. In large
population studies, researchers have found that people with an affected first-degree relative, such as a
parent or sibling, have a four to nine percent higher chance of developing Parkinson’s, as compared to
the general population. This means that if a person’s parent has Parkinson’s; his or her chances of
developing the disease are slightly higher than the risk among the general population.

6. How is Parkinson’s diagnosed?

There is no standard test to conclusively show if a person has Parkinson’s disease. Because of this, it can
often be difficult to diagnose. The disease should be diagnosed by a neurologist with experience and
training in assessing and treating Parkinson’s, ideally a movement disorder specialist. Physicians rely on
a neurological examination and the individual’s descriptions of symptoms to determine whether he or
she has Parkinson’s. A neurologist may order several tests to rule out other conditions before diagnosing
a person with Parkinson’s disease.

7. How do you treat Parkinson’s?

Although there is currently no cure for Parkinson’s, there are treatment options available such as
medication and surgery to manage its symptoms. Levodopa is the most widely prescribed Parkinson’s
medication, and people often take several other medications to manage the disease. Surgical options,
such as deep brain stimulation, may help alleviate a person’s Parkinson’s symptoms if and when they
stop responding favorably to medication. However, surgery is only effective for a small group of people
with Parkinson’s and is only recommended if an individual meets specific criteria. ( we can name our
products )

8. Can people die from Parkinson’s?

Parkinson’s disease is a progressive disorder, and although it is not considered to be a fatal disease,
symptoms do worsen over time and make life difficult. People with Parkinson’s experience a significantly
decreased quality of life and are often unable to perform daily movement functions, such as getting out
of bed unaided and driving. Most individuals are eventually forced to stop working due to the
unavoidable progression of disabling symptoms. In some cases, people have died from Parkinson’s-
related complications, such as pneumonia.
THE VALUE OF EARLY DIAGNOSIS AND TREATMENT IN PARKINSON’S DISEASE

Parkinson’s disease (PD) is a chronic progressive neurodegenerative disease affecting approximately 7

million people globally with devastating socioeconomic effects on individuals, their families and society.

MISSED OR MISDIAGNOSIS AND DELAYS IN TREATMENT. There is no diagnostically conclusive test for PD
yet, so the diagnosis is clinical in nature. In the clinical setting, PD is commonly missed or misdiagnosed
since many symptoms of PD are also common to other diseases both neurodegenerative and non-
neurodegenerative. The diagnosis and treatment of PD typically occurs when the disease has already
progressed to a relatively advanced stage in which motor symptoms are clearly evident and substantial
neurophysiological damage has already taken place. At this point, any possibility of delaying disease
progression or, achieving neuro protection may already be out of reach.

New developments in early diagnosis and treatment.

A revised definition of PD, together with the availability of novel diagnostic tools can allow for earlier
diagnosis, and therefore treatment. Non-motor symptoms, which account for a large proportion of PD
symptoms and usually emerge much earlier, are increasingly recognized as useful indicators to achieve
earlier diagnosis. Furthermore, a number of new and diverse diagnostic tools (i.e. biological and genetic
biomarkers, imaging techniques) are now available and have the potential to make earlier diagnosis, and
consequently earlier treatment, possible.

The benefits of early diagnosis and treatment.

The most evident benefit of early treatment with medicines other than L-dopa is the reduction in
symptoms (for example difficulty or distortion in performing voluntary movements) and the delay of
levodopa (L-dopa) initiation and therefore its immediate side-effects (for example hypotension,
arrhythmia, insomnia and hallucinations) and the effects of its chronic administration (motor
complications and drug resistance). Clinical trials also suggest that early treatment can slow disease
progression.

WHY EARLY INTERVENTION AND ADHERENCE ARE IMPORTANT IN PD?

EARLY INTERVENTION : There is growing evidence that early intervention may help in preserving the
functioning of the neurons, reducing symptoms, particularly difficulty or distortion in performing
voluntary movements, slowing disease progression and improving patient QoL. However early
treatment relies on early diagnosis and, as already pointed out, early diagnosis and treatment of PD can
be difficult to achieve because the nature of diagnosis (mostly clinical). Therefore by the time motor
symptoms emerge, significant neurological damage and the destructive structural changes have already
taken place. PD diagnosis by conventional means identifies a disease which is already advanced, and any
possibility of delaying disease progression, not to mention neuroprotection, may already be out of
reach. Despite the fact that diagnosis remains mainly clinical, recently, the increasing recognition of pre-
motor symptoms together with a number of new and diverse techniques for diagnosis have the
potential to considerably alter the diagnostic landscape in the next future, making the early diagnosis,
and therefore treatment, achievable.

ADHERENCE: Poor treatment adherence is a significant challenge to optimizing outcomes in PD, and any
therapeutic strategy must take into consideration those factors impacting treatment adherence.

** the graph is needed to be added **

Early diagnosed vs late diagnosed or misdiagnosed.

 ‫فِهمِمرضِالرعاشِ"ِالباركنسون"‬

‫ِ‬

‫‪ِ.1‬ماِهوِمرضِالرعاشِ“الباركنسون"ِ؟ ِ‬
‫ِ‬
‫مرضِالرعاشِ(الباركنسون)ِهوِاضطرابِالحركةِالمزمنةِوالتقدمٌةِالتًِتنطويِعلىِخللِوموتِالخالٌاِالعصبٌةِالحٌوٌةِفًِالدماغ‪ِ.‬‬
‫بعضِهذهِالخالٌاِالعصبٌةِالمٌتةِتنتجِالدوبامٌن‪ِ،‬وهًِمادةِكٌمٌائٌةِترسلِرسائلِإلىِجزءِالدماغِالذيٌِتحكمِفًِالحركةِوالتنسٌق‪ِ.‬وِ‬
‫معِتقدمِمرضِباركنسون‪ِ،‬تقلِكمٌةِالدوبامٌنِالمنتجةِفًِالدماغِ‪ِ،‬وتتركِالشخصِغٌرِقادرِعلىِالسٌطرةِعلىِالحركة‪.‬‬
‫ِ‬

‫ِ‬

‫‪.2‬ماِهًِأعراضِمرضِالرعاشِ؟ِ ِ‬

‫األعراضِالحركٌةِالرئٌسٌةِاألربعةِلمرضِباركنسونِهًِرعشةِالٌدٌنِوالذراعٌنِوالساقٌنِأوِالفك‪ِِ.‬تصلبِفًِاألطرافِوالجذع‪ِ.‬‬
‫بطءِالحركةِ‪ِ,‬ضعفِالتوازنِوالتنسٌق‪ِ.‬األعراضِالشائعةِاألخرىِقدِتشملِاأللم‪ِ ,‬االرتباك‪ِ ,‬إعٌاء‪ِ ,‬اضطراباتِالنوم؛ِكآبة؛ِاإلمساك‪ِ.‬‬
‫التغٌراتِالمعرفٌة؛ِالخوفِأوِالقلق؛ِوالمشاكلِالبولٌة‪ِ.‬كلِهذهِاألعراضٌِمكنِأنِتختلفِمنِشخصِآلخر‪.‬‬

‫اٌشعبػ "ثبسوٕغ‪ "ْٛ‬؟‬ ‫‪.3‬وُ عذد اٌّقبث‪ ٓ١‬ثّشك‬

‫‪٠ٚ‬ع‪١‬ؼ ِب ‪٠‬مذس ثٕح‪ِ 10 ٛ‬ال‪ ٓ١٠‬ؽخـ ف‪ ٟ‬خّ‪١‬ع أٔحبء اٌعبٌُ ِع ِشك ثبسوٕغ‪٠ .ْٛ‬ع‪١‬ؼ ِب‬
‫‪٠‬قً إٌ‪ ْٛ١ٍِ ٝ‬ؽخـ ِع ِشك ثبسوٕغ‪ ٛ٘ٚ ،ْٛ‬أوثش ِٓ اٌعذد اإلخّبٌ‪ٌ ٟ‬ألؽخبؿ اٌز‪ ٓ٠‬رُ‬
‫رؾخ‪١‬ق‪ ُٙ‬ثبٌزقٍت اٌّزعذد‪ٚ ،‬مّ‪ٛ‬س اٌعنالد ‪ِٚ‬شك ٌ‪ ٛ‬خ‪ٙ١‬ش‪٠‬ح‪٠ .‬زُ رؾخ‪١‬ـ ِب ‪٠‬مشة ِٓ‬
‫‪ 60،000‬ؽخـ ِع ِشك ثبسوٕغ‪ ْٛ‬وً عبَ‪٘ٚ ،‬زا اٌعذد ال ‪٠‬عىظ ا‪٢‬الف ِٓ اٌحبالد اٌز‪ٌُ ٟ‬‬
‫‪٠‬زُ اٌىؾف عٕ‪ٙ‬ب‪ .‬حذ‪ٚ‬س ص‪٠‬بدح ف‪ِ ٟ‬عذي ثبسوٕغ‪ِ ْٛ‬ع اٌزمذَ ف‪ ٟ‬اٌغٓ‪ٌٚ ،‬ىٓ ِب ‪٠‬مذس‬
‫ثٕح‪ ٛ‬أسثعخ ف‪ ٟ‬اٌّئخ ِٓ األؽخبؿ اٌز‪٠ ٓ٠‬عبٔ‪ِ ِٓ ْٛ‬شك ثبسوٕغ‪٠ ْٛ‬زُ رؾخ‪١‬ق‪ ُٙ‬لجً عٓ‬
‫‪ٚ .50‬لذ أظ‪ٙ‬شد اإلحقبءاد أْ اٌشخبي أوثش عشمخ لٍ‪١‬ال ٌذاء ثبسوٕغ‪ ِٓ ْٛ‬إٌغبء‪.‬‬
‫ِ‬

‫"ثبسوٕغ‪ "ْٛ‬؟‬ ‫‪ِ.4‬ب ٘‪ ٛ‬عجت ِشك اٌشعبػ‬

‫‪ٚ‬وّب ٘‪ ٛ‬اٌحبي ِع اٌعذ‪٠‬ذ ِٓ االميشاثبد اٌعقج‪١‬خ‪ ،‬ال ‪٠‬عشف عجت ِشك ثبسوٕغ‪ِٚ .ْٛ‬ع‬
‫رٌه‪ ،‬فئْ اٌعٍّبء ‪ٚ‬اٌجبحث‪٠ ٓ١‬عٍّ‪ ْٛ‬خب٘ذ‪ٌٍ ٓ٠‬ىؾف عٓ األعجبة اٌّحزٍّخ ‪ ,‬ثّب ف‪ٟ‬‬
‫رٌه اٌع‪ٛ‬اًِ اٌ‪ٛ‬ساث‪١‬خ ‪ٚ‬اٌج‪١‬ئ‪١‬خ‪ٌّ ،‬شك ثبسوٕغ‪.ْٛ‬‬
‫ِ‬

‫ِ‬

‫‪٠ ً٘ .5.‬عزجش ِٕشك اٌشعبػ " اٌجبسوٕغ‪ِ " ْٛ‬شك ‪ٚ‬ساث‪ ٟ‬؟‬
‫عٍ‪ ٝ‬اٌشغُ ِٓ أْ اٌغبٌج‪١‬خ اٌعظّ‪ ِٓ ٝ‬حبالد ثبسوٕغ‪١ٌ ْٛ‬غذ ِ‪ٛ‬س‪ٚ‬ثخ ِجبؽشح‪ٚ ،‬لذ‬
‫اوزؾف اٌجبحث‪ ْٛ‬اٌعذ‪٠‬ذ ِٓ اٌد‪ٕ١‬بد اٌز‪ّ٠ ٟ‬ىٓ أْ رغجت اٌّشك ف‪ ٟ‬عذد لٍ‪ ِٓ ً١‬األعش‪.‬‬
‫اٌجح‪ٛ‬س عٍ‪٘ ٝ‬زٖ األؽىبي اٌ‪ٛ‬ساث‪١‬خ إٌبدسح رغبُ٘ إٌ‪ ٝ‬حذ وج‪١‬ش ف‪ ٟ‬رعض‪٠‬ض ف‪ ُٙ‬خّ‪١‬ع‬
‫اٌز‪ٓ٠‬‬ ‫األؽخبؿ‬ ‫أْ‬ ‫اٌجبحث‪ْٛ‬‬ ‫‪ٚ‬خذ‬ ‫اٌىج‪١‬شح‪،‬‬ ‫اٌغىبٔ‪١‬خ‬ ‫اٌذساعبد‬ ‫ف‪ٟ‬‬ ‫اٌّشك‪.‬‬ ‫أؽىبي‬
‫‪٠‬عبٔ‪ ِٓ ْٛ‬لش‪٠‬ت ِٓ اٌذسخخ األ‪ ٌٝٚ‬اٌّزنشسح‪ِ ،‬ثً أحذ اٌ‪ٛ‬اٌذ‪ ٓ٠‬أ‪ ٚ‬األخ‪ٌ ،‬ذ‪ ُٙ٠‬فشفخ‬
‫أوجش ِٓ أسثعخ إٌ‪ ٝ‬رغعخ ف‪ ٟ‬اٌّئخ ٌزي‪٠ٛ‬ش ثبسوٕغ‪ ،ْٛ‬ثبٌّمبسٔخ ِع عبِخ اٌغىبْ‪.‬‬
‫‪٘ٚ‬زا ‪٠‬عٕ‪ ٟ‬أٔٗ إرا وبْ أحذ اٌ‪ٛ‬اٌذ‪ٌ ٓ٠‬ذ‪ ٗ٠‬ثبسوٕغ‪ْٛ‬؛ فئْ فشفٗ ف‪ ٟ‬ري‪٠ٛ‬ش اٌّشك‬
‫أعٍ‪ ٝ‬لٍ‪١‬ال ِٓ اٌّخبىش ث‪ ٓ١‬عبِخ اٌغىبْ‪.‬‬
‫ِ‬

‫‪ .6‬و‪١‬ف ‪٠‬زُ رؾخ‪١‬ـ ِشك اٌجبسوٕغ‪ْٛ‬؟‬

‫ال ‪ٛ٠‬خذ اخزجبس ِع‪١‬بس‪ ٞ‬إلظ‪ٙ‬بس ِب إرا وبْ اٌؾخـ ِقبة ثّشك ثبسوٕغ‪ٚ .ْٛ‬ثغجت ٘زا‪،‬‬
‫فئٔٗ غبٌجب ِب ‪٠‬ى‪ ِٓ ْٛ‬اٌقعت رؾخ‪١‬ـ‪ٕ٠ٚ .‬جغ‪ ٟ‬رؾخ‪١‬ـ ٘زا اٌّشك اوٍ‪١ٕ١‬ى‪١‬ب ِٓ لجً‬
‫ىج‪١‬ت األعقب ة ِع اٌخجشح ‪ٚ‬اٌزذس‪٠‬ت ف‪ ٟ‬رم‪ٚ ُ١١‬عالج اٌجبسوٕغ‪ ِٓ ،ْٛ‬إٌبح‪١‬خ اٌّثبٌ‪١‬خ‬
‫اٌّقبة‬ ‫اٌؾخـ‬ ‫‪ٚٚ‬فف‬ ‫اٌعقج‪ٟ‬‬ ‫اٌفحـ‬ ‫عٍ‪ٝ‬‬ ‫‪٠‬عزّذ‪ْٚ‬‬ ‫األىجبء‬ ‫اٌحشوخ‪.‬‬ ‫اميشاة‬ ‫أخقبئ‪ٟ‬‬
‫ِدّ‪ٛ‬عخ‬ ‫‪٠‬زيٍت‬ ‫لذ‬ ‫األعقبة‬ ‫ىج‪١‬ت‬ ‫ثبسوٕغ‪.ْٛ‬‬ ‫ٌذ‪/ٗ٠‬ا‬ ‫وبْ‬ ‫إرا‬ ‫ِب‬ ‫ٌزحذ‪٠‬ذ‬ ‫ٌألعشاك‬
‫العزجعبد اٌؾش‪ٚ‬ه األخش‪ ٜ‬لجً رؾخ‪١‬ـ افبثخ ؽخـ ِٓ ِشك ثبسوٕغ‪ِ ْٛ‬د‪ٛٙ‬ي‬ ‫اٌفح‪ٛ‬فبد‬
‫اٌغجت‪.‬‬
‫**ِمتالزمةِسرٌرٌةِباركنسونِتضمِ‪ِ :‬‬

‫الضمورِمتعددِاالجهزةِ–ِالشللِفوقِالنودىِالمتزاٌدِ–ِالتنكسِالقشرىِالقاعدى ِ‬

‫كماٌِنتجِعنِ‪ِ :‬‬

‫اخذِبعضِاالدوٌةِمثلِالمهدئاتِالعظمىِ‪ِ,‬مضاداتِالقئِ‪ِ,‬اضطرباتِاالوعٌةِالدموٌةِالمخٌةِ‪ِ.‬المرضِالدماغى‪ِ,‬بعضِالسمومِمثلِ‬
‫اولِاكسٌدِالكربون‪ِ,‬المبٌداتِالحشرٌةِ‪ِ,‬اصاباتِالرأسِوِبعضِاالمراضِالوراثٌةِمثلِمرضِوٌلسونِهانجنتونِوِاٌضاِمضاعفاتِ‬
‫االمراضِالسرطانٌةِ‪ِ .‬‬

‫‪7.‬كٌفِتتعاملِمعِمرضِالباركنسون؟ ِ‬

‫ِهناك ِالعدٌد ِمن ِالطرق ِالعالجٌة ِالدواء ِوالجراحة ِللتحكم ِأعراض ِ ِلٌفودوبا ِ‪,‬هو ِالدواء ِاألكثر ِشٌوعا ِعلى ِنطاق ِواسع ِفً ِمرضِ‬
‫الباركنسون‪ِ،‬والناسِغالباِماِتؤخذِالعدٌدِمنِاألدوٌةِاألخرىِللسٌطرةِعلىِاعراضِالمرض‪ِ.‬قدِتساعدِالخٌاراتِالجراحٌة‪ِ،‬مثلِالتحفٌزِ‬
‫العمٌقِللدماغ‪ِ،‬علىِالتخفٌفِمنِأعراضِشخصِباركنسونِإذاِتوقفتِعنِاالستجابةِبشكلِإٌجابً ِلألدوٌة‪ِ.‬ومعِذلك‪ِ،‬الجراحةِهًِ‬
‫فعالةِفقطِلمجموعةِصغٌرةِمنِالمرضًِالمصابٌنِِفقطِإذاِكانِالفردٌِلبًِمعاٌٌرِمحددة‪ِ .‬‬

‫‪ّ٠ ً٘ .8‬ىٓ أْ ‪٠‬غجت ِشك اٌجبسوٕغ‪ ْٛ‬اٌ‪ٛ‬فبٖ؟‬

‫ِشك ثبسوٕغ‪ ٛ٘ ْٛ‬اميشاة رمذِ‪ٚ ،ٟ‬عٍ‪ ٝ‬اٌشغُ ِٓ أٔٗ ال ‪٠‬عزجش ِشمب ِّ‪١‬زب‪ٚ ،‬األعشاك‬
‫ِشك‬ ‫ِٓ‬ ‫‪٠‬عبٔ‪ْٛ‬‬ ‫اٌز‪ٓ٠‬‬ ‫إٌبط‬ ‫فعجخ‪.‬‬ ‫اٌح‪١‬بح‬ ‫‪ٚ‬ردعً‬ ‫اٌ‪ٛ‬لذ‬ ‫ِش‪ٚ‬س‬ ‫ِع‬ ‫ع‪ٛ‬ءا‬ ‫رضداد‬
‫اٌجبسوٕغ‪ ْٛ‬أخفنذ ثؾىً ٍِح‪ ًٛ‬خ‪ٛ‬دح اٌح‪١‬بح ‪ٚ‬غبٌجب ِب رى‪ ْٛ‬غ‪١‬ش لبدسح عٍ‪ ٝ‬أداء‬
‫‪ٚ‬ظبئف اٌحشوخ اٌ‪١ِٛ١‬خ‪ِ ،‬ثً اٌخش‪ٚ‬ج ِٓ اٌغش‪٠‬ش د‪ِ ْٚ‬غبعذح ‪ٚ‬اٌم‪١‬بدح‪٠ٚ .‬دجش ِعظُ‬
‫األفشاد ف‪ٙٔ ٟ‬ب‪٠‬خ اٌّيبف عٍ‪ ٝ‬اٌز‪ٛ‬لف عٓ اٌعًّ ثغجت اٌزمذَ اٌز‪ ٞ‬ال ِفش ِٕٗ ٌألعشاك‬
‫اٌّعيٍخ‪ .‬ف‪ ٟ‬ثعل اٌحبالد‪ ،‬ر‪ٛ‬ف‪ ٟ‬إٌبط ِٓ ِنبعفبد اٌّشك‪ِ ،‬ثً االٌز‪ٙ‬بة اٌشئ‪.ٞٛ‬‬
‫ِِ‬
 ‫قٌمةِالتشخٌصِالمبكرِوالعالجِفًِمرضِالرعاشِ"ِالباركنسون"‬

‫ِ‬

‫ِمرض ِباركنسون ِهو ِمرض ِعصبً ِتدرٌجً ِمزمن ٌِإثر ِعلى ِحوالً ِ‪ِ 7‬مالٌٌن ِشخص ِفً ِجمٌع ِأنحاء ِالعالم ِمع ِآثار ِاجتماعٌةِ‬
‫واقتصادٌةِمدمرةِعلىِاألفرادِوأسرهمِوالمجتمع ِ‬

‫‪.‬سوءِأوِالتشخٌصِالخاطئِأوالتؤخٌرِفًِالعالج‪ِ.‬الٌِوجدِاختبارِقاطعِتشخٌصًِمرضِالرعاشِحتىِاآلن‪ِ،‬وبالتالًِفإنِالتشخٌصِ‬
‫بواسطةِالكشفِالطبً ِ‪ِ،‬وعادةِماٌِتمِعدمِالتشخٌص ِأوِتشخصِخطؤِحٌث ِالعدٌدِمنِأعراضِتتشاركِنفسِاالعراضِ‪ِ .‬عادةِ ِستمِ‬
‫التعرفِعلًِالمرضِعندماِقدِتقدمِبالفعلِإلىِمرحلةِمتقدمةِنسبٌاِحٌثِاألعراضِالحركٌةِواضحةِبشكلِواضحِوالضررِالعصبًِ‬
‫كبٌرِقدِحدثِبالفعل‪ِ.‬عندِهذهِالنقطة‪ِ،‬أيِإمكانٌةِلتؤخٌرِتطورِالمرض‪ِ،‬أوِتحقٌقِالحماٌةِالعصبٌةِقدِتكونِبالفعلِبعٌدةِالمنال‪.‬‬

‫اٌزي‪ٛ‬ساد اٌدذ‪٠‬ذح ف‪ ٟ‬اٌزؾخ‪١‬ـ اٌّجىش ‪ٚ‬اٌعالج‪.‬‬

‫حذ‪٠‬ثب ِع ر‪ٛ‬افش أد‪ٚ‬اد اٌزؾخ‪١‬ـ اٌدذ‪٠‬ذح‪ ،‬اٌزؾخ‪١‬ـ اٌّجىش‪ٚ ،‬ثبٌزبٌ‪ ٟ‬اٌعالج‪ .‬األعشاك‬
‫‪ٚ‬عبدح ِب رظ‪ٙ‬ش ف‪ٚ ٟ‬لذ عبثك‬ ‫غ‪١‬ش اٌحشو‪١‬خ‪ ،‬اٌز‪ ٟ‬رّثً ٔغجخ وج‪١‬شح ِٓ أعشاك اٌّشك‬
‫ثىث‪١‬ش‪٠ ،‬زُ اٌزعشف عٍ‪ٔ ٝ‬ح‪ِ ٛ‬زضا‪٠‬ذ وّؤؽشاد ِف‪١‬ذح ٌزحم‪١‬ك اٌزؾخ‪١‬ـ اٌّجىش‪ٚ .‬عال‪ٚ‬ح‬
‫اٌعالِبد‬ ‫(أ‪ٞ‬‬ ‫‪ٚ‬اٌّزٕ‪ٛ‬عخ‬ ‫اٌدذ‪٠‬ذح‬ ‫اٌزؾخ‪١‬ق‪١‬خ‬ ‫األد‪ٚ‬اد‬ ‫ِٓ‬ ‫عذد‬ ‫ٕ٘بن‬ ‫رٌه‪،‬‬ ‫عٍ‪ٝ‬‬
‫اٌج‪ٌٛٛ١‬خ‪١‬خ اٌج‪ٌٛٛ١‬خ‪١‬خ ‪ٚ‬اٌ‪ٛ‬ساث‪١‬خ‪ٚ ،‬رمٕ‪١‬بد اٌزق‪٠ٛ‬ش) ِزبحخ ا‪ٌٚ ْ٢‬ذ‪ٙ٠‬ب اٌمذسح عٍ‪ٝ‬‬
‫إخشاء اٌزؾخ‪١‬ـ اٌّجىش‪ٚ ،‬ثبٌزبٌ‪ ٟ‬اٌعالج اٌّجىش‪ ،‬افجح ِّىٕب‪.‬‬
‫ِ‬

‫ف‪ٛ‬ائذ اٌزؾخ‪١‬ـ اٌّجىش ‪ٚ‬اٌعالج‪.‬‬

‫إْ اٌفبئذح األوثش ‪ٚ‬م‪ٛ‬حب ِٓ اٌعالج اٌّجىش ثأد‪٠ٚ‬خ أخش‪ ٜ‬غ‪١‬ش اٌٍ‪١‬ف‪ٛ‬د‪ٚ‬ثب (ساِ‪١‬ىغ‪ٛ‬ي)‬
‫٘‪ ٟ‬اٌحذ ِٓ األعشاك (عٍ‪ ٝ‬عج‪ ً١‬اٌّثبي فع‪ٛ‬ثخ أ‪ ٚ‬رؾ‪ ٗ٠ٛ‬ف‪ ٟ‬أداء اٌحشوبد اٌي‪ٛ‬ع‪١‬خ)‬
‫‪ٚ‬رأخ‪١‬ش ٌ‪١‬ف‪ٛ‬د‪ٚ‬ثب (‪-L‬د‪ٚ‬ثب) ‪ٚ‬ثبٌزبٌ‪ ٟ‬آثبسٖ اٌدبٔج‪١‬خ اٌّجبؽشح (ي ِثً أخفبك مغو‬
‫اٌذَ‪ ،‬عذَ أزظبَ مشثبد اٌمٍت‪ٚ ،‬األسق ‪ٚ‬اٌ‪ٍٛٙ‬عخ)‪ٚ .‬رؾ‪١‬ش اٌزدبسة اٌّعٍّ‪١‬خ أ‪٠‬نب‬
‫إٌ‪ ٝ‬أْ اٌعالج اٌّجىش ‪ّ٠‬ىٓ أْ ‪٠‬جيئ ري‪ٛ‬س اٌّشك‪.‬‬
‫ِ‬

‫ِِ‬
 ‫ِ‬

‫ٌّبرا ‪٠‬عزجش االوزؾبف ‪ ٚ‬اٌزذخً اٌّجىش عبًِ ِ‪ ُٙ‬ف‪ ٟ‬اٌغ‪١‬يشح عٍ‪ِ ٟ‬شك اٌشعبػ ؟‬

‫اٌزذخً اٌّجىش‪ٕ٘ :‬بن أدٌخ ِزضا‪٠‬ذح عٍ‪ ٝ‬أْ اٌزذخً اٌّجىش لذ ‪٠‬غبعذ ف‪ ٟ‬اٌحفبً عٍ‪ٝ‬‬
‫عًّ اٌخال‪٠‬ب اٌعقج‪١‬خ‪ٚ ،‬اٌحذ ِٓ األعشاك‪ٚ ،‬خبفخ فع‪ٛ‬ثخ أ‪ ٚ‬رؾ‪ ٗ٠ٛ‬ف‪ ٟ‬أداء اٌحشوبد‬
‫اٌي‪ٛ‬ع‪١‬خ‪ٚ ،‬رجبىؤ ري‪ٛ‬س اٌّشك ‪ٚ‬رحغ‪ٚ ٓ١‬ظبئف اٌّش‪٠‬ل‪ِٚ .‬ع رٌه ‪٠‬عزّذ اٌعالج اٌّجىش‬
‫عٍ‪ ٝ‬اٌزؾخ‪١‬ـ اٌّجىش‪ٚ ،‬وّب أؽ‪١‬ش ِٓ لجً‪ٚ ،‬اٌزؾخ‪١‬ـ اٌّجىش ‪ٚ‬اٌعالج ِٓ اٌجبسوٕغ‪ْٛ‬‬
‫‪ّ٠‬ىٓ أْ ‪٠‬ى‪ ِٓ ْٛ‬اٌقعت رحم‪١‬مٗ ألْ ىج‪١‬عخ اٌزؾخ‪١‬ـ (ِعظّ‪ٙ‬ب ث‪ٛ‬اعيخ اٌىؾف)‪ٌ .‬زٌه ِٓ‬
‫لجً ظ‪ٛٙ‬س األعشاك اٌحشو‪١‬خ‪ٚ ،‬لذ ‪ٚ‬لعذ ثبٌفعً رٍف عقج‪ ٟ‬وج‪١‬ش ‪ٚ‬اٌزغ‪١‬شاد اٌ‪١ٙ‬ىٍ‪١‬خ‬
‫ثبٌ‪ٛ‬عبئً اٌزمٍ‪١‬ذ‪٠‬خ ‪٠‬حذد اٌّشك اٌز‪ ٛ٘ ٞ‬ثبٌفعً‬ ‫اٌّذِشح‪ .‬رؾخ‪١‬ـ ِشك اٌشعبؽ‪ٟ‬‬
‫ِزمذِخ‪ٚ ،‬أ‪ ٟ٠‬إِىبٔ‪١‬خ ٌزأخ‪١‬ش ري‪ٛ‬س اٌّشك‪ٔ ،‬ب٘‪١‬ه عٓ اٌحّب‪٠‬خ اٌعقج‪١‬خ‪ ،‬لذ رى‪ْٛ‬‬
‫ثبٌفعً ثع‪١‬ذا عٓ ِزٕب‪ٚ‬ي اٌ‪١‬ذ‪.‬‬
‫األخ‪١‬شح‪،‬‬ ‫ا‪ٔٚ٢‬خ‬ ‫ف‪ٟ‬‬ ‫اٌيج‪١‬ت‪،‬‬ ‫ث‪ٛ‬اعيخ‬ ‫أعبعب‬ ‫‪٠‬ضاي‬ ‫ال‬ ‫اٌزؾخ‪١‬ـ‬ ‫أْ‬ ‫ِٓ‬ ‫اٌشغُ‬ ‫عٍ‪ٝ‬‬
‫اٌزمٕ‪١‬بد‬ ‫ِٓ‬ ‫عذد‬ ‫ِع‬ ‫خٕت‬ ‫إٌ‪ٝ‬‬ ‫خٕجب‬ ‫اٌحشو‪١‬خ‬ ‫لجً‬ ‫ِب‬ ‫ألعشاك‬ ‫اٌّزضا‪٠‬ذ‬ ‫‪ٚ‬االعزشاف‬
‫اٌدذ‪٠‬ذح ‪ٚ‬اٌّزٕ‪ٛ‬عخ ٌٍزؾخ‪١‬ـ ٌذ‪ٙ٠‬ب اٌمذسح عٍ‪ ٝ‬رغ‪١١‬ش وج‪١‬ش ف‪ ٟ‬اٌّؾ‪ٙ‬ذ اٌزؾخ‪١‬ق‪ ٟ‬ف‪ٟ‬‬
‫اٌّغزمجً اٌّمجً‪ِّ ،‬ب ‪٠‬دعً اٌزؾخ‪١‬ـ اٌّجىش‪ٚ ٚ ،‬ثبٌزبٌ‪ ٟ‬اٌعالج‪ّ٠ ،‬ىٓ رحم‪١‬مٗ‪.‬‬
‫ِشك‬ ‫ف‪ٟ‬‬ ‫اٌّثٍ‪ٝ‬‬ ‫إٌزبئح‬ ‫ٌزحم‪١‬ك‬ ‫وج‪١‬شا‬ ‫رحذ‪٠‬ب‬ ‫‪٠‬ؾىً‬ ‫االٌزضاَ‬ ‫ع‪ٛ‬ء‬ ‫‪:‬‬ ‫االٌزضاَ‬
‫اٌجبسوٕغ‪ٚ ،ْٛ‬أ‪ ٞ‬اعزشار‪١‬د ‪١‬خ عالخ‪١‬خ ‪٠‬دت أْ رأخز ثع‪ ٓ١‬االعزجبس رٍه اٌع‪ٛ‬اًِ اٌز‪ٟ‬‬
‫رؤثش عٍ‪ ٝ‬االٌزضاَ اٌعالج‪.‬‬
Eva Pharma is a revolutionary generic drug company that is driven by finding innovative
solutions to raise the health standard in the nations where it operates through making
effective, safe and affordable medication available to all.

At Eva Pharma, we place emphasis on more than just being a revolutionary generic drug
manufacturer. Our consistent efforts to find cutting edge solutions and raising the bar of
healthcare standards are the mandates that drive us. In every country we operate in, we
strive to make a difference. Not only through the manufacturing of safe and affordable
medication, but also by making it available to all who need it.

As one of the fastest growing drug manufacturers in the MENA region, we see it as an
integral part of our mission to establish a genuine personal connection with our patients
and the physicians that deliver care to them. One that helps us identify their needs and
allows us to re-align our resources and expertise to best serve them.

For us, it’s a matter of manufacturing the most needed affordable drugs and selling
them in an ethical manner. We see our role as one that involves several considerations.
Be that social, environmental, or a commitment to our people and patients, we
continually strive to bring the full potential of our company to bear in the local, regional
and international arenas.

Our aim is to become Egypt’s largest pharmaceutical company and one of the top
three leading pharmaceutical companies in the MENA region by 2020. Our vision is to
achieve multinational status through increasing our international sales to rival our
domestic sales. We are on a rigorous path to top our international success by becoming
one of the world’s top twenty generic drug manufacturers by 2029.